|Year : 2014 | Volume
| Issue : 2 | Page : 227-230
Primary diffuse leptomeningeal gliomatosis: An autopsy case report
Shaik Afshan Jabeen1, Arikapadu Haritha Chowdary1, Rukmini Mridula Kandadai1, Megha S. Uppin2, Angamattu Kanikannan Meena1, Rupam Borgohain1, Challa Sundaram2
1 Department of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, India
2 Department of Pathology, Nizam's Institute of Medical Sciences, Hyderabad, India
|Date of Submission||21-Nov-2012|
|Date of Decision||02-Jan-2013|
|Date of Acceptance||09-Feb-2013|
|Date of Web Publication||17-May-2014|
Shaik Afshan Jabeen
Department of Neurology, Nizam's Institute of Medical Sciences, Punagutta, Hyderabad
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Primary diffuse leptomeningeal gliomatosis (PDLG) is a rare condition, characterized by infiltration of the meninges by glial cells without evidence of the primary tumor in the brain or spinal cord parenchyma. Glioma arising primarily from the leptomeninges is extremely rare and often diagnosed only in post mortem examination and the diagnosis may be missed in meningeal biopsy. We describe a young female who presented with symptoms of raised intracranial pressure with imaging evidence of diffuse leptomeningeal enhancement in whom autopsy confirmed the diagnosis of PDLG. Our case illustrates the diagnostic difficulties in making the pre-mortem diagnosis even with multiple cerebrospinal fluid cytologies and leptomeningeal biopsy.
Keywords: Chronic meningitis, leptomeningeal gliomatosis, meningeal biopsy, neoplastic meningitis
|How to cite this article:|
Jabeen SA, Chowdary AH, Kandadai RM, Uppin MS, Meena AK, Borgohain R, Sundaram C. Primary diffuse leptomeningeal gliomatosis: An autopsy case report. Ann Indian Acad Neurol 2014;17:227-30
|How to cite this URL:|
Jabeen SA, Chowdary AH, Kandadai RM, Uppin MS, Meena AK, Borgohain R, Sundaram C. Primary diffuse leptomeningeal gliomatosis: An autopsy case report. Ann Indian Acad Neurol [serial online] 2014 [cited 2021 Dec 6];17:227-30. Available from: https://www.annalsofian.org/text.asp?2014/17/2/227/132647
| Introduction|| |
Primary diffuse leptomeningeal gliomatosis (PDLG) is a rare, fatal disease characterized by infiltration of the meninges by glial cells without evidence of primary tumor in the brain or spinal cord parenchyma. [1.2] This condition was first described by Moore in 1954. Primary leptomeningeal glioma can be in the form of a solitary tumor or a diffuse tumor involving intracranial or spinal cord leptomeninges. The typical signs and symptoms are indicative of increased intracranial pressure, cranial neuropathies, and seizures. Due to the non-specific nature of clinical presentation, ante mortem diagnosis poses a challenge to the clinician. About one-third of all the cases were diagnosed only on post mortem studies.
| Case Report|| |
A 22-year-old lady, presented with headache, vomiting, double vision, swaying while walking and tremor of left upper limb since 20 days. There was no history of fever, seizures, altered sensorium, and focal weakness and the past history was unremarkable. General and systemic examinations were normal. Neurological examination revealed bilateral papilledema, left sixth nerve paresis with action tremor and signs of cerebellar dysfunction in left upper limb. There were no meningeal signs. Rest of the examination was normal.
Magnetic resonance imaging (MRI) brain showed diffuse, thick leptomeningeal enhancement [Figure 1]a with few nodular enhancing meningeal lesions in right cerebellomedullary cistern [Figure 1]b. The brain parenchyma and ventricles were normal.
|Figure 1: (a) T1 weighted axial magnetic resonance imaging brain with gadolinium contrast showing diffuse, thick leptomeningeal enhancement (black arrow) with normal brain parenchyma and ventricles and (b) thick nodular leptomeningeal enhancement in cerebellomedullary cistern (black arrow)|
Click here to view
Lumbar punctures were performed four times during the course of illness [Table 1]. All the cerebrospinal fluid (CSF) samples showed elevated protein (up to 1.2 g/dl) and normal glucose levels. Though all the lumbar punctures were atraumatic, all CSF samples showed red blood cells (RBCs) (200-2,000/dl). There were few (0-100/dl) white blood cells. Smears and cultures for acid fast bacilli including DNA polymerase chain reaction for mycobacterium tuberculosis were negative. Gram stain, aerobic, and anaerobic cultures, fungal stains and fungal cultures were also negative on repeated testing. Large volumes of CSF analyzed with cytospin did not show any evidence of malignant cells. CSF angiotensin converting enzyme levels were normal. Complete hemogram, liver, and renal function tests were normal. Serological markers for vasculitis were negative. Mantoux test was non-reactive. Contrast enhanced computed tomography scans of chest and abdomens were normal. HIV and HBsAg serology were negative.
A diagnosis of chronic meningitis with raised intracranial pressure was considered. Possible etiological considerations were infectious (tuberculous or fungal), non-infectious inflammatory (sarcoidosis or other vasculitides) or neoplastic (primary meningeal or secondary carcinomatous) meningitis.
A meningeal with brain biopsy was obtained from left temporal region. Histopathology showed normal brain tissue with lymph mononuclear infiltrate in one of the dural vessels with vessel wall destruction without any granulomas or fungal elements.
She was empirically treated with anti-tuberculous drugs and there was no improvement. Short course of steroids were given. She continued to deteriorate, became comatose and succumbed to the illness after about 8 weeks from the onset of her symptoms. A partial autopsy (confined to brain) was carried out after obtaining consent from her parents.
On opening the dura, the temporal lobe was seen herniating out which corresponded to the biopsy site. The brain weighted 1,200 g on fixing for 4 weeks and there was evidence of cerebral edema. The base of the brain showed a whitish material plastering over the superior surface of cerebellum and entrapping the vessels of circle of Willis and lower cranial nerves [Figure 2]. Multiple coronal sections of the brain showed normal cortex and white matter. There was no evidence of a mass lesion. Sections from the cortical and basal meninges revealed a cellular lesion with fibrillary background. The cells showed marked pleomorphism with giant cells and brisk mitotic activity. Focal area showed necrosis and microvascular proliferation [Figure 3]. The cells showed strong expression of glial fibrillary acidic protein (GFAP), vimentin and S-100 whereas CD99, LCA and synaptophysin were negative. Epidermal growth factor (EGFR) was positive and p53 showed nuclear positivity in almost 60% of tumor cells [Figure 4]. The tumor was restricted to leptomeninges and multiple sections through parenchyma did not reveal any microscopic focus of tumor. In view of the morphologic and immunohistochemical features, a diagnosis of primary leptomeningeal gliomatosis was made and graded as glioblastoma (WHO grade IV) in view of presence of mitosis, necrosis, and microvascular proliferation.
|Figure 2: The base of the brain seen to be plastered by thick whitish exudative material encasing the vessels of circle of Willis and basal cranial nerves|
Click here to view
|Figure 3: (a) Tumor cells seen over the surface of cerebellum (H and E, ×40) (b, c) Tumor cells showing pleomorphism, atypical mitosis, giant cells and fi brillary background (H and E, ×400) (d) Foci of microvascular proliferation (H and E, ×200)|
Click here to view
|Figure 4: Immunohistochemical profi le of tumor with cytoplasmic positivity for glial fibrillary acidic protein (GFAP) (a) Vimentin (b) epidermal growth factor (EGFR) (c) GFAP×40, Vim, EGFR HRP×200 (d) P53 showing nuclear positivity in almost all the tumor nuclei. (p53×200)|
Click here to view
| Discussion|| |
Leptomeningeal gliomatosis is uncommon, but should be considered in-patients presenting with neurological symptoms suggestive of meningitis or raised intracranial pressure and leptomeningeal enhancement on MRI especially, if they do not respond to conventional treatment. The differential diagnosis is extensive and includes, infectious, inflammatory, granulomatous, and neoplastic conditions. This condition may be commonly mistaken for tuberculous meningitis especially, in endemic areas.  It is challenging to have an ante mortem diagnosis as PDLG can have varying and non-specific clinical features, time course, and progression of the illness. According to Cooper and Kernohan,  the definite diagnosis of PDLG is based on the following criteria: No apparent attachment of extra medullary meningeal tumor to the neural parenchyma, no evidence of primary neoplasia within the neuraxis, and the existence of distinct leptomeningeal encapsulation around the tumor.
The clinical manifestations of PDLG are non-specific and those of raised intracranial pressure, which is seen in about 80% of the cases at presentation, cranial nerve palsies (35%), seizures (29%) being the most common.  Though focal neurological deficits have been described, cerebellar signs at presentation have not been reported previously. Our patient had clinical features suggestive of raised intracranial pressure with sixth nerve palsy, bilateral papilloedema and asymmetric cerebellar deficits probably due to the location of a focal nodular enhancing lesion in cerebello-medullary cistern encasing the inferior cerebellar peduncle. Presence of nodular non-enhancing lesions over the cerebellum without any related clinical involvement had been previously reported.  Common neuroradiological findings in PDLG include ventriculomegaly with diffuse or focal leptomeningeal contrast enhancement. The spinal cord may be predominantly involved. , Our patient showed similar, though non-specific features like diffuse and thick cranial leptomeningeal enhancement with few nodular extra medullary enhancing lesions in cerebello-medullary cistern.
CSF analysis in PDLG may reveal decreased or normal glucose, elevated protein, and pleocytosis. Our patient had lymphocytic pleocytosis and all the samples showed plenty of RBC. This is the second case to our knowledge to report consistent presence of CSF RBCs.  CSF cytology is usually unremarkable in PDLG. Cytologies were positive in 5 of 45 reported cases, only once in the first sample examined.  CSF cytology for malignant cells was negative in our patient and it is suggested to do GFAP staining in CSF cytospin to detect cells of glial origin.  The negative CSF cytology could be related to the inability of glioma cells to detach from the primary focus, because of a desmoplastic reaction limiting the dissemination of tumor cells.
Surgical biopsy should be performed in areas with contrast enhancement in MRI. In a review of 24 published autopsy proven cases of PDLG, 16 patients underwent ante mortem biopsy of which histology missed the diagnosis in 5 cases.  We performed a meningeal with brain biopsy near the temporal lobe where there was thick meningeal enhancement. However, the biopsy did not show any tumor cells. Difficulty of obtaining a positive CSF cytology and diagnostic leptomeningeal biopsy has also been highlighted previously and consideration of multi-site or repeat leptomeningeal biopsy has been emphasized.  There are three cases published in literature where the initial leptomeningeal biopsy was non-diagnostic but a repeat biopsy was useful. ,, One possible explanation for non-diagnostic leptomeningeal biopsies in PDLG may be the predilection for the leptomeningeal involvement to be the most prominent at the skull base, compared to the cerebral hemispheres, where biopsies are commonly performed and also due to the presence of skip lesions.
Based on the definition of PDLG, a post mortem morphological study of the entire neuraxis should be required to confirm the diagnosis. The morphologhic subtype of PDLG is usually a high-grade astrocytoma, oligodendroglioma or gliosarcoma. A single case of pilocytic astrocytoma presenting as PDLG has been reported.
Other tumors, which can have primary leptomeningeal distribution includes ependymoblastoma, primary neuroectodermal tumor (PNET), melanocytoma, and lymphoma. Immunohistochemistry and morphology helps in identifying the particular subtype. Positivity for GFAP, vimentin and S-100 helped in diagnosis of glioblastoma in the present case. Some of the PNETs can also show glial differentiation however, negativity for CD99 and synaptophysin ruled out the possibility of PNET.
A molecular and genetic basis in the biology of different grades of glioblastoma has been well-established. EGFR amplification is the hallmark of primary glioblastoma multi-forme (GBM) whereas the secondary GBMs are characterized by mutations of P53 gene. The present case showed immunohistochemical expression of both P53 and EGFR though we did not have flourescence in situ hybridization analysis. Loss of P53 and phosphatase and tensin homolog gene tumor suppressor gene has been described in PDLG earlier. Other genetic attribute to PDLG has been described in the form of Neurofibromatosis 1 (NF1) mutations by King et al. They have reported PDLG in a 12 year old child involving central and spinal meninges. Presence of additional mutations in addition to neurofibromin is shown to give rise to more malignant tumors in the NF1 patients.
In high-grade gliomatosis, prognosis remains poor. Mean survival time after diagnosis is 4 months. Only few cases have been reported to respond to chemotherapy and craniospinal irradiation. ,
| Conclusion|| |
Leptomeningeal gliomatosis should be suspected in cases of unexplained subacute or chronic meningeal processes. On the basis of the lack of specificity concerning symptoms and CSF data, PDLG is often misinterpreted as being of infectious or autoimmune origin with tuberculous meningitis being considered as the most common clinical diagnosis. Meningeal biopsy may be inconclusive. Prognosis is universally poor. Review of previous case reports and detailed analysis of our case suggests a need for high-suspicion of PDLG in the presence of raised intra cranial pressure early in the clinical course with marked leptomeningeal enhancement on imaging. Presence of CSF RBC may be the clue in few cases.
| References|| |
|1.||Cooper IS, Kernohan JW. Heterotopic glial nests in the subarachnoid space; histopathologic characteristics, mode of origin and relation to meningeal gliomas. J Neuropathol Exp Neurol 1951;10:16-29. |
|2.||Yomo S, Tada T, Hirayama S, Tachibana N, Otani M, Tanaka Y, et al. A case report and review of the literature. J Neurooncol 2007;81:209-16. |
|3.||Ruiz-Ares G, Collantes-Bellido E, Rodriguez de Rivera F, Medina-Báez J, Palomo-Ferrer F, Morales-Bastos C, et al. Primary diffuse leptomeningeal gliomatosis mimicking meningeal tuberculosis. Neurologist 2011;17:160-3. |
|4.||Debono B, Derrey S, Rabehenoina C, Proust F, Freger P, Laquerrière A. Primary diffuse multinodular leptomeningeal gliomatosis: Case report and review of the literature. Surg Neurol 2006;65:273-82. |
|5.||Kastenbauer S, Danek A, Klein W, Yousry TA, Bise K, Reifenberger G, et al. Primary diffuse leptomeningeal gliomatosis: Unusual MRI with non-enhancing nodular lesions on the cerebellar surface and spinal leptomeningeal enhancement. J Neurol Neurosurg Psychiatry 2000;69:385-8. |
|6.||Smirniotopoulos JG, Murphy FM, Rushing EJ, Rees JH, Schroeder JW. Patterns of contrast enhancement in the brain and meninges. Radiographics 2007;27:525-51. |
|7.||Baborie A, Dunn EM, Bridges LR, Bamford JM. Primary diffuse leptomeningeal gliomatosis predominantly affecting the spinal cord: Case report and review of the literature. J Neurol Neurosurg Psychiatry 2001;70:256-8. |
|8.||Dietrich PY, Aapro MS, Rieder A, Pizzolato GP. Primary diffuse leptomeningeal gliomatosis (PDLG): A neoplastic cause of chronic meningitis. J Neurooncol 1993;15:275-83. |
|9.||Wechsler LR, Gross RA, Miller DC. Meningeal gliomatosis with "negative" CSF cytology: The value of GFAP staining. Neurology 1984;34:1611-5. |
|10.||Ko MW, Turkeltaub PE, Lee EB, Gonatas NK, Volpe NJ, Moster ML, et al. Primary diffuse leptomeningeal gliomatosis mimicking a chronic inflammatory meningitis. J Neurol Sci 2009;278:127-31. |
|11.||Beauchesne P, Pialat J, Duthel R, Barral FG, Clavreul G, Schmitt T, et al. Aggressive treatment with complete remission in primary diffuse leptomeningeal gliomatosis: A case report. J Neurooncol 1998;37:161-7. |
|12.||Gonçalves AL, Masruha MR, Carrete H Jr, Stávale JN, Silva NS, Vilanova LC. Primary diffuse leptomeningeal gliomatosis. Arq Neuropsiquiatr 2008;66:85-7. |
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
|This article has been cited by|
||Primary diffuse leptomeningeal glioneuronal tumors of the central nervous system: Report of three cases and review of literature
| ||Chenue Abongwa, Jennifer Cotter, Benita Tamrazi, Girish Dhall, Tom Davidson, Ashley Margol |
| ||Pediatric Hematology and Oncology. 2020; 37(3): 248 |
|[Pubmed] | [DOI]|
||Diffuse leptomeningeal gliomatosis initially presenting with intraventricular hemorrhage: a case report and literature review
| ||Min Zhu,JunJun Zheng,Yuanzhao Zhu,Hui Wan,Yuchen Wu,Daojun Hong |
| ||BMC Neurology. 2015; 15(1) |
|[Pubmed] | [DOI]|